Skip to main content
. Author manuscript; available in PMC: 2015 Apr 30.
Published in final edited form as: J Hematop. 2013 Mar;6(1):11–18. doi: 10.1007/s12308-012-0166-4

Fig. 3.

Fig. 3

Multivariate survival solution of overall survival with rituximab therapy. The CPH survival solution when patients are treated with rituximab is stratified by CD36 expression, R-IPI scoring, and FASN expression. The classic R-IPI scoring prognostic value is seen with low scores predicting longer survival. Low FASN expression and CD36 overexpression also predict a longer survival. L low, H high, O overexpression